FDA proposal positive for Endo if finalized, says B. Riley FBR

B. Riley FBR analyst David Buck believes the FDA proposal to remove vasopressin, which is active in Endo’s Vasostrict, from 503 Bulks List, which allows compounding, is a net positive for Vasostrict if it becomes finalized. He notes that Vasostrict accounts for 15% of Endo’s sales. The analyst reiterates a Buy rating on the shares with an $18.50 price target.

https://bit.ly/2wslWdn